Artifacts screening

Apply published and in-house filters for toxic reactive moieties in addition to those that lead to screening artifacts... 

To avoid confusion, here we use the term pharmacologically promiscuous compound to refer to compounds that are truly active on several drug targets and the term screening artifact to describe compounds that are active in an assay for any reason other than specific activity toward the protein target of interest. 

When a compound interferes with an assay such that it leads to an apparently positive result, this is a screening artifact. There are various possible mechanisms of assay interference, and it is therefore important to understand the screening assay(s) and... 

Our BioProfile approach makes it easily possible for research project teams to access information about cross-reactivities within a given hit set. This information can be used to prioritize compounds or compound classes. It is also used to check for potential selectivity targets or counter-screens and to identify screening artifacts. Identification of fi equent hitters in the screening collection is anoth example of use. 

High throughput screening 6.1 Detection of screening artifacts... 

System specification proceeds much as before but has an added element of user-interface design. The normal artifacts of system specification—a type model and operation specs—are now accompanied by prototypes and UI specs describing the screens, dialog flows across windows, information presented and required, and reports. These user-interface elements are kept consistent with the type model and are reviewed through scenarios. 

Lastly, it is important to visualize plates to obtain a graphical overview of the screen. To this end we have developed a Plate Viewer to create heatmaps and an R template in KNIME to generate scatter plots of screening campaigns. These tools allow to visualize row and column artifacts and to compare the performance of various plate batches during a screening campaign. 

---